MarginsXMarginsX
Home › Markets › Health Care › OSTX

OS Therapies Incorporated (OSTX)

OSTX trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.6807
-8.63% on the day
Market cap
$35.4M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerOSTX on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNot reported by the screener
IPO year2024
SEC CIK0001795091
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
0.1 months
$205K cash at June 30, 2026
Share count, 1 year
+44.6%
2025-08-13 to 2026-08-12
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued."
10-Q 2026-08-14
Cash and burn$205K cash; operating cash flow -$4.6M a quarter.Report 2026-06-30
Shares outstanding46,125,825 (2026-08-12); 31,891,933 a year earlier.Cover page 2026-08-12
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-08-21
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorMaloneBailey, LLP, Houston, Texas, United StatesPCAOB Form AP 2026-04-20
Late filings, 12 months1 NT noticeNT 10-Q 2026-05-15
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$8.6M-$5.5M$205KNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$10.4M-$4.6M$918K$1.3MNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$13.5M-$3.7M$270KNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$6.9M-$4.7M$1.9MNo debt tagsNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed-$4.5M-$2.4M$2.8MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$3.9M-$3.4M$3.0MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$3.0M-$2.4M$5.5MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$2.9M-$3.4M$1.9MNo debt tagsNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B72026-09-10
Latest annual report
ANNUAL REPORT
10-K2026-03-31
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-16
Latest current report
CURRENT REPORT
8-K2026-11-12
Latest proxy
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A2026-07-24

Source: SEC EDGAR submissions feed, 248 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-25.5%
1 month-48.6%
3 months-53.4%
Year to date-46.8%
1 year-59.1%
From 52-week high-66.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TELOTelomir Pharmaceuticals Inc.$0.4810-1.96%$35.4M
VERUVeru Inc.$2.08-0.48%$35.5M
ATHEAlterity Therapeutics Limited$1.960.00%$35.7M
RNTXRein Therapeutics Inc.$0.4000-27.55%$34.5M
GRCEGrace Therapeutics Inc.$1.75-3.31%$36.8M
SERSerina Therapeutics Inc.$1.42+2.16%$37.7M
BMEABiomea Fusion Inc.$0.5201-10.67%$37.8M
HYPDHyperion DeFi Inc.$2.47-4.26%$38.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier